razoxane has been researched along with Myeloproliferative Disorders in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belt, R; Haas, C; Hoogstraten, B; Liesmann, J | 1 |
| Begg, CB; Glick, JH; O'Connell, MJ; Oken, MM; Silverstein, MN | 1 |
| Bruckner, HW; Lokich, JJ; Stablein, DM | 1 |
1 trial(s) available for razoxane and Myeloproliferative Disorders
| Article | Year |
|---|---|
Randomized clinical trial comparing two dose regimens of ICRF-159 in refractory malignant lymphomas.
Topics: Adult; Aged; Clinical Trials as Topic; Female; Hodgkin Disease; Humans; Leukopenia; Lymphoma; Male; Middle Aged; Myeloproliferative Disorders; Piperazines; Probability; Prognosis; Razoxane; Thrombocytopenia | 1980 |
2 other study(ies) available for razoxane and Myeloproliferative Disorders
| Article | Year |
|---|---|
Phase I evaluation of ICRF-187 (NSC-169780) in patients with advanced malignancy.
Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Granulocytes; Humans; Infusions, Parenteral; Leukocyte Count; Leukopenia; Myeloproliferative Disorders; Neoplasms; Piperazines; Platelet Count; Razoxane | 1981 |
Studies of Baker's antifol, methotrexate, and razoxane in advanced gastric cancer: A Gastrointestinal Tumor Study Group Report.
Topics: Adenocarcinoma; Antineoplastic Agents; Female; Gastrointestinal Neoplasms; Humans; Male; Methotrexate; Middle Aged; Myeloproliferative Disorders; Prognosis; Random Allocation; Razoxane; Triazines | 1982 |